ethyl (3-fluoro-4-methoxybenzoyl)acetate | 195708-39-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl (3-fluoro-4-methoxybenzoyl)acetate
• 英文别名: Ethyl 3-(3-fluoro-4-methoxyphenyl)-3-oxopropanoate
• CAS: 195708-39-5
• 化学式: C₁₂H₁₃FO₄
• mdl: MFCD07783532
• 分子量: 240.231
• InChiKey: ZRGDBZPTJMTOMF-UHFFFAOYSA-N

物化性质

• 沸点：
  340.9±27.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl (3-fluoro-4-methoxybenzoyl)acetate 在 Ra-Ni 盐酸 、 sodium hydroxide 、 氢气 、 sodium cyanoborohydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 溶剂黄146 、 异丙醇 、 乙腈 为溶剂， 反应 23.5h， 生成 ethyl (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-[3-chloropropylsulfonyl(propyl)amino]ethyl]-2-(3-fluoro-4-methoxyphenyl)pyrrolidine-3-carboxylate
  参考文献：
  名称：

  Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 2. Sulfonamide-Based ET_A/ET_B Mixed Antagonists

  摘要：

  When the N,N-dialkylacetamide side chain of the highly ETA-selective endothelin antagonist ABT-627 (1; [2R,3R,4S]-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-[[(N,N-dibutylamino)carbonyl]methyl]pyrrolidine-3-carboxylic acid; A-147627) is replaced by N,S-dialkylsulfonamidoethyl, the resultant analogs retain ETA affinity, but exhibit substantial ETB affinity as well. Structure-activity studies reveal that modifications in the length of the two alkyl groups, and in the substitution on the anisyl ring, are important in optimizing this ''balanced'' antagonist profile. In particular the combination of an N-n-propyl group, an S-alkyl chain between four and six carbons in length, and a fluorine atom ortho to the aromatic OCH3 provides compounds with sub-nanomolar affinities for both receptor subtypes, and with ETA/ETB ratios close to 1. A number of these compounds also exhibit oral bioavailabilities (in rats) in the 30-50% range and have substantial plasma half-lives. The balanced receptor-binding profile of these potent and orally bioavailable compounds complements the ETA selectivity observed with 1.

  DOI：

  10.1021/jm970101g
• 作为产物：
  描述：

  3-氟-4-甲氧基苯甲酸 、 ethyl potassium malonate 在 N,N'-羰基二咪唑 、 magnesium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 ethyl (3-fluoro-4-methoxybenzoyl)acetate
  参考文献：
  名称：

  Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 5. Highly Selective, Potent, and Orally Active ET_A Antagonists

  摘要：

  The synthesis and structure-activity relationships (SAR) of a series of pyrrolidine-3-carboxylic acids as endothelin antagonists are described. The data shows an increase in selectivity when the methoxy of Atrasentan (ABT-627) is replaced with methyl, and the benzodioxole is replaced with dihydrobenzofuran. Adding a fluorine further increases the binding activity and provides a metabolically stable and orally bioavailable ETA-selective antagonist.

  DOI：

  10.1021/jm010237l

文献信息

• Endothelin antagonists
  申请人：Abbott Laboratories

  公开号：US06162927A1

  公开（公告）日：2000-12-19

  A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

  公开了一种具有以下化学式（I）的化合物：##STR1##或其药用可接受的盐，以及制备该化合物的方法、中间体，以及一种拮抗内皮素的方法。
• [EN] PHENYL GUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS<br/>[FR] PHENYL-GUINOLINES ET LEUR UTILISATION COMME MODULATEURS DES RECEPTEURS D'OESTROGENES
  申请人：WYETH CORP

  公开号：WO2004103973A1

  公开（公告）日：2004-12-02

  This invention provides estrogen receptor modulators of formula: (I), having the structure wherein, R1, R2, R3, R4, R5 and R6 are as defined in the specification, or a N-oxide thereof or a pharmaceutically acceptable salt thereof or a prodrug thereof.

  这项发明提供了式(I)的雌激素受体调节剂，其结构如下，其中R1、R2、R3、R4、R5和R6如规范中所定义，或其N-氧化物、药用可接受盐或前药。
• ERβ ligands. Part 4: Synthesis and structure–activity relationships of a series of 2-phenylquinoline derivatives
  作者：An T. Vu、Stephen T. Cohn、Eric S. Manas、Heather A. Harris、Richard E. Mewshaw

  DOI：10.1016/j.bmcl.2005.07.008

  日期：2005.10

  A new class of estrogen receptor beta (ERbeta) ligands based on the 2-phenylquinoline scaffold was prepared. Several analogues with C4 substitution displayed high affinity (3-5 nM) and significant selectivity (up to 83-fold) for ERbeta. The best compound, 13b, was profiled as a selective partial agonist for ERbeta at 1 muM in a cell-based transcriptional assay. Uterine weight bioassay of 13b indicated

  制备了基于2-苯基喹啉支架的一类新的雌激素受体β（ERbeta）配体。几种具有C4取代的类似物对ERbeta表现出高亲和力（3-5 nM）和显着选择性（高达83倍）。在基于细胞的转录测定中，最好的化合物13b被鉴定为1μM时ERbeta的选择性部分激动剂。13b的子宫重量生物测定表明体内没有激活ERalpha。
• Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1)
  作者：Philippe G Nantermet、James C Barrow、George F Lundell、Janetta M Pellicore、Kenneth E Rittle、MaryBeth Young、Roger M Freidinger、Thomas M Connolly、Cindra Condra、Jerzy Karczewski、Rodney A Bednar、Stanley L Gaul、Robert J Gould、Kris Prendergast、Harold G Selnick

  DOI：10.1016/s0960-894x(01)00745-4

  日期：2002.2

  The synthesis and biological evaluation of a series of nonpeptidic small molecule antagonists of the human platelet thrombin receptor (PAR-1) are described. Optimization of the 5-amino-3-arylisoxazole lead resulted in an approximate 100-fold increase in potency. The most potent of these compounds (54) inhibits platelet activation with IC50S of 90 nM against the thrombin receptor agonist peptide (TRAP) and 510 nM against thrombin as the agonist. Further, antagonist 54 fully blocks platelet aggregation stimulated by 1 nM thrombin for 10 min. (C) 2002 Published by Elsevier Science Ltd.
• Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 5. Highly Selective, Potent, and Orally Active ET_A Antagonists
  作者：Hwan-Soo Jae、Martin Winn、Thomas W. von Geldern、Bryan K. Sorensen、William J. Chiou、Bach Nguyen、Kennan C. Marsh、Terry J. Opgenorth

  DOI：10.1021/jm010237l

  日期：2001.11.1

  The synthesis and structure-activity relationships (SAR) of a series of pyrrolidine-3-carboxylic acids as endothelin antagonists are described. The data shows an increase in selectivity when the methoxy of Atrasentan (ABT-627) is replaced with methyl, and the benzodioxole is replaced with dihydrobenzofuran. Adding a fluorine further increases the binding activity and provides a metabolically stable and orally bioavailable ETA-selective antagonist.